2026-02-27 08:45Financial Performance - Total revenue for 2025 reached RMB 249,842.03 million, a year-on-year increase of 28.23% compared to RMB 194,831.73 million in the previous year[3] - The net loss attributable to shareholders of the parent company was RMB 87,438.94 million, a significant reduction from RMB 128,092.64 million in the previous year[3] - The weighted average return on equity improved to -14.70%, an increase of 5.01 percentage points from -19.71% in the previous year[3] - The company expects a net profit attributable to shareholders of the parent company, excluding stock payment impacts, to be around RMB -79,798.56 million, a reduction in loss of approximately 37.70% year-on-year[5] Product Performance - The core product, Toripalimab injection (brand name: Tuoyi®), saw a sales revenue increase of approximately 37.72% in the domestic market[6] - Toripalimab has been approved for 12 indications in mainland China, all included in the national medical insurance catalog[6] Assets and Investments - The total assets at the end of the reporting period were RMB 1,238,904.33 million, reflecting a 14.91% increase from RMB 1,078,196.04 million at the beginning of the period[3] Research and Development - The company is advancing multiple innovative drugs in clinical trials, including JS207, which is currently in Phase II trials[7] Strategic Focus - The company is focused on enhancing commercialization capabilities while controlling costs, leading to a significant narrowing of net losses compared to the previous year[7] - The company has expanded its global commercialization network, with Toripalimab approved in over 40 countries and regions[6]